89 related articles for article (PubMed ID: 36335418)
1. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
2. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.
Bettiol A; Urban ML; Padoan R; Groh M; Lopalco G; Egan A; Cottin V; Fraticelli P; Crimi C; Del Giacco S; Losappio L; Moi L; Cinetto F; Caminati M; Novikov P; Berti A; Cameli P; Cathébras P; Coppola A; Durel CA; Folci M; Lo Gullo A; Lombardi C; Monti S; Parronchi P; Rivera CM; Solans R; Vacca A; Espígol-Frigolé G; Guarnieri G; Bianchi FC; Marchi MR; Tcherakian C; Kahn JE; Iannone F; Venerito V; Desaintjean C; Moroncini G; Nolasco S; Costanzo GAML; Schroeder JW; Ribi C; Tesi M; Gelain E; Mattioli I; Bello F; Jayne D; Prisco D; Vaglio A; Emmi G;
Lancet Rheumatol; 2023 Dec; 5(12):e707-e715. PubMed ID: 38251561
[TBL] [Abstract][Full Text] [Related]
3. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis.
Davanzo F; Marchi MR; Iorio L; Bortoli M; Doria A; Padoan R
Autoimmun Rev; 2024 Mar; 23(3):103503. PubMed ID: 38101691
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
[TBL] [Abstract][Full Text] [Related]
5. Coexistence of Eosinophilic Granulomatosis With Polyangiitis and Allergic Bronchopulmonary Aspergillosis: A Fascinating Relationship.
Marra AM; Curci P; Franco G; Pittalis G; Tugnoli E; Cavasin D; Cristiano A; Bini F
Cureus; 2024 Apr; 16(4):e57917. PubMed ID: 38601813
[TBL] [Abstract][Full Text] [Related]
6. Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy.
Faverio P; Bonaiti G; Bini F; Vaghi A; Pesci A
Ther Clin Risk Manag; 2018; 14():2385-2396. PubMed ID: 30573961
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection.
Takano T; Inutsuka Y; Nakamura S; Ando N; Komori M
Respirol Case Rep; 2021 Aug; 9(8):e00810. PubMed ID: 34306708
[TBL] [Abstract][Full Text] [Related]
8. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases.
Del Pozo V; Bobolea I; Rial MJ; Espigol-Frigolé G; Solans Laqué R; Hernández-Rivas JM; Mora E; Crespo-Lessmann A; Izquierdo Alonso JL; Domínguez Sosa MS; Maza-Solano J; Atienza-Mateo B; Bañas-Conejero D; Moure AL; Rúa-Figueroa Í
Front Immunol; 2023; 14():1310211. PubMed ID: 38250075
[TBL] [Abstract][Full Text] [Related]
9. Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence.
Caminati M; Micheletto C; Norelli F; Olivieri B; Ottaviano G; Padoan R; Piacentini G; Schiappoli M; Senna G; Menzella F
Expert Opin Biol Ther; 2024; 24(1-2):15-23. PubMed ID: 38197326
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options.
Żychowska M; Tutka K; Reich A
Dermatol Ther (Heidelb); 2020 Aug; 10(4):893-899. PubMed ID: 32578132
[TBL] [Abstract][Full Text] [Related]
11. Eosinophil-associated diseases: the allergist's and clinical immunologist's perspective.
Marra AM; Rossi CM; Piga MA; Moroncini G; Bilò MB
Eur Ann Allergy Clin Immunol; 2024 Mar; ():. PubMed ID: 38546414
[TBL] [Abstract][Full Text] [Related]
12. Is there a Role for Anti-IL-5 Therapies in Eosinophilic Fasciitis?
Angelopoulos A; Kouverianos I; Daoussis D
Mediterr J Rheumatol; 2023 Dec; 34(4):414-417. PubMed ID: 38282929
[TBL] [Abstract][Full Text] [Related]
13. Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti-interleukin-5 receptor antibody.
Takimoto T; Kagawa T; Tachibana K; Arai T; Inoue Y
Respirol Case Rep; 2020 Aug; 8(6):e00599. PubMed ID: 32566229
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-5 Antagonist Monoclonal Antibody Therapy Improves Symptoms and Reduces Steroid Dependence in Eosinophilic Myocarditis Patients.
Trovato V; Asada A; Fussner L; Curtis C; Kahwash R
JACC Case Rep; 2024 Apr; 29(7):102267. PubMed ID: 38645295
[TBL] [Abstract][Full Text] [Related]
15. Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA).
Bandla M; Howard M; McNally A; Armstrong D; Simpson I; Mar A
Australas J Dermatol; 2023 Aug; 64(3):404-407. PubMed ID: 37195732
[TBL] [Abstract][Full Text] [Related]
16. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
[TBL] [Abstract][Full Text] [Related]
17. A confluence of advanced treatment options for atopic dermatitis, eosinophilic lung diseases and chronic urticaria brought about by the revolutionary discovery of biologics and Janus kinase inhibitors.
Bellanti JA; Settipane RA
Allergy Asthma Proc; 2022 Nov; 43(6):471-473. PubMed ID: 36335419
[No Abstract] [Full Text] [Related]
18. Benralizumab in the management of rare primary eosinophilic lung diseases.
Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
[No Abstract] [Full Text] [Related]
19. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
